News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kos Pharmaceuticals (KOSP) Announces Strategic Investment In Triad Pharmaceuticals Giving Kos Access To New Chemical Entities In Key Therapeutic Areas


10/19/2005 5:12:39 PM

CRANBURY, N.J.--(BUSINESS WIRE)--Feb. 7, 2005-- -- Kos completes $4 million of its aggregate $8 million equity investment in privately held drug discovery and drug design pharmaceutical company -- Investment complements sponsored research arrangement previously made with Triad centered on discovery and design of novel regulators for HDL cholesterol Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that it has made a strategic investment in Triad Pharmaceuticals, Inc. ("Triad"), a privately held drug discovery and design pharmaceutical company focused on developing molecules for a variety of diseases, including orally active therapies for cholesterol disorders, diabetes and cancer. The strategic initiative consists of an aggregate $8 million equity investment, which builds on its ongoing sponsored research arrangement, in which, on behalf of Kos, Triad is designing and synthesizing certain new chemical entities that regulate HDL (the "good") cholesterol. This alliance with Triad will broaden Kos' research and development efforts to include the discovery and synthesis of new chemical entities, leveraging Kos' existing competency in drug delivery and development.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES